---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-214740"
form_type: "8-K"
ticker: "ELVN"
cik: "0001672619"
company_name: "Enliven Therapeutics, Inc."
filed_at: "2021-07-14T23:59:59+00:00"
generated_at: "2026-06-30T05:26:41.313644+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Imara prices $50M public offering of 8.33M shares at $6.00 each; net proceeds ~$46.8M

## Summary
- Offering of 8,333,333 shares priced at $6.00/share for gross proceeds of $50M.
- Net proceeds expected to be ~$46.8M after underwriting discounts and offering expenses.
- Underwriters granted 30-day option to purchase up to 1,249,999 additional shares ($7.5M).
- Closing expected July 16, 2021; Morgan Stanley, SVB Leerink, and Cantor are joint book-runners.
- Company is a clinical-stage biotech focused on rare hemoglobin disorders; proceeds for general corporate purposes.

## SEC filing metadata
- accession: 0001193125-21-214740
- form_type: 8-K
- ticker: ELVN
- cik: 0001672619
- company_name: Enliven Therapeutics, Inc.
- filed_at: 2021-07-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672619/000119312521214740/0001193125-21-214740-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672619/000119312521214740/d138853d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-214740
- JSON: https://secwatch.observer/filing/0001193125-21-214740.json
- Plain text: https://secwatch.observer/filing/0001193125-21-214740.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.